NTLA

SEC source: 0001209191-21-054315 · doc4.xml · nonDerivative · entry 2

Goddard Glenn · CIK 0001581992 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,496

F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $152.75 to $153.62, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price.

SEC source: 0001209191-21-054315 · doc4.xml · nonDerivative · entry 1

Goddard Glenn · CIK 0001581992 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,200

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-053305 · doc4.xml · derivative · entry 6

LEONARD JOHN M · CIK 0001563584 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 224,138

Underlying: Common Stock · 27,139 shares

Expires 2030-03-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 134,583 shares as of August 23, 2021.

SEC source: 0001209191-21-053305 · doc4.xml · nonDerivative · entry 4

LEONARD JOHN M · CIK 0001563584 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 719,305

F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

SEC source: 0001209191-21-053305 · doc4.xml · nonDerivative · entry 3

LEONARD JOHN M · CIK 0001563584 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 719,405

F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $152.38 to $153.12, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 23, 2021 at each separate price.

SEC source: 0001209191-21-053305 · doc4.xml · nonDerivative · entry 2

LEONARD JOHN M · CIK 0001563584 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 727,570

F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.38 to $152.18, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 23, 2021 at each separate price.

SEC source: 0001209191-21-053305 · doc4.xml · nonDerivative · entry 1

LEONARD JOHN M · CIK 0001563584 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 746,444

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-052835 · doc4.xml · derivative · entry 6

LEONARD JOHN M · CIK 0001563584 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 251,277

Underlying: Common Stock · 22,682 shares

Expires 2030-03-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 134,583 shares as of August 19, 2021.

SEC source: 0001209191-21-052835 · doc4.xml · nonDerivative · entry 4

LEONARD JOHN M · CIK 0001563584 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 719,305

F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $152.055 to $152.80, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 19, 2021 at each separate price.

SEC source: 0001209191-21-052835 · doc4.xml · nonDerivative · entry 3

LEONARD JOHN M · CIK 0001563584 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 725,268

F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.02 to $152.015, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 19, 2021 at each separate price.

SEC source: 0001209191-21-052835 · doc4.xml · nonDerivative · entry 2

LEONARD JOHN M · CIK 0001563584 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 732,261

F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.00 to $150.96, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 19, 2021 at each separate price.

SEC source: 0001209191-21-052835 · doc4.xml · nonDerivative · entry 1

LEONARD JOHN M · CIK 0001563584 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 741,987

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-050881 · doc4.xml · derivative · entry 3

Lebwohl David · CIK 0001810882 · EVP, Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 197,600

Underlying: Common Stock · 2,400 shares

Expires 2030-05-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 62,500 shares as of August 9, 2021.

SEC source: 0001209191-21-050881 · doc4.xml · nonDerivative · entry 2

Lebwohl David · CIK 0001810882 · EVP, Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 791

F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

F2 · balance_after: Includes 568 and 223 shares acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on December 31, 2020 and June 30, 2021, respectively.

SEC source: 0001209191-21-050881 · doc4.xml · nonDerivative · entry 1

Lebwohl David · CIK 0001810882 · EVP, Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,191

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-050225 · doc4.xml · derivative · entry 5

Goddard Glenn · CIK 0001581992 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,000

Underlying: Common Stock · 20,000 shares

Expires 2028-10-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 61,875 shares as of August 5, 2021.

SEC source: 0001209191-21-050225 · doc4.xml · nonDerivative · entry 4

Goddard Glenn · CIK 0001581992 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $152.01 to $152.38, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 5, 2021 at each separate price.

SEC source: 0001209191-21-050225 · doc4.xml · nonDerivative · entry 3

Goddard Glenn · CIK 0001581992 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 530

F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.015 to $151.99, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 5, 2021 at each separate price.

SEC source: 0001209191-21-050225 · doc4.xml · nonDerivative · entry 2

Goddard Glenn · CIK 0001581992 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,098

F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.01 to $151.00, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 5, 2021 at each separate price.

SEC source: 0001209191-21-050225 · doc4.xml · nonDerivative · entry 1

Goddard Glenn · CIK 0001581992 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-050228 · doc4.xml · derivative · entry 9

Sepp-Lorenzino Laura · CIK 0001777421 · EVP, Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 109,000

Underlying: Common Stock · 26,000 shares

Expires 2030-03-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F9 · derivative.exercise_date: The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 53,437 shares as of August 4, 2021.

SEC source: 0001209191-21-050228 · doc4.xml · nonDerivative · entry 8

Sepp-Lorenzino Laura · CIK 0001777421 · EVP, Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,391

F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

F8 · balance_after: Includes shares acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan as follows: 760 shares on December 31, 2019; 847 shares on June 30, 2020; 561 shares on December 31, 2020 and 223 shares on June 30, 2021.

SEC source: 0001209191-21-050228 · doc4.xml · nonDerivative · entry 7

Sepp-Lorenzino Laura · CIK 0001777421 · EVP, Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,517

F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $140.395 to $141.04, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 4, 2021 at each separate price.

SEC source: 0001209191-21-050228 · doc4.xml · nonDerivative · entry 6

Sepp-Lorenzino Laura · CIK 0001777421 · EVP, Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,571

F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $139.395 to $140.37, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 4, 2021 at each separate price.

SEC source: 0001209191-21-050228 · doc4.xml · nonDerivative · entry 5

Sepp-Lorenzino Laura · CIK 0001777421 · EVP, Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,343

F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $138.31 to $139.305, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 4, 2021 at each separate price.

SEC source: 0001209191-21-050228 · doc4.xml · nonDerivative · entry 4

Sepp-Lorenzino Laura · CIK 0001777421 · EVP, Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,762

F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $137.255 to $138.25, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 4, 2021 at each separate price.

SEC source: 0001209191-21-050228 · doc4.xml · nonDerivative · entry 3

Sepp-Lorenzino Laura · CIK 0001777421 · EVP, Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,106

F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $136.25 to $137.24, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 4, 2021 at each separate price.

SEC source: 0001209191-21-050228 · doc4.xml · nonDerivative · entry 2

Sepp-Lorenzino Laura · CIK 0001777421 · EVP, Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,920

F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $135.18 to $135.885, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 4, 2021 at each separate price.

SEC source: 0001209191-21-050228 · doc4.xml · nonDerivative · entry 1

Sepp-Lorenzino Laura · CIK 0001777421 · EVP, Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,391

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-045513 · doc4.xml · derivative · entry 1

BASTA JAMES · CIK 0001792726 · EVP, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 130,000

Underlying: Common Stock · 130,000 shares

Expires 2031-06-30

F1 · derivative.exercise_date: This option was granted on July 1, 2021 with respect to 130,000 shares of Common Stock, with 25% vesting on July 1, 2022 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter.

SEC source: 0001104659-21-086607 · tm2120917-1_4seq1.xml · nonDerivative · entry 18

FORMELA JEAN FRANCOIS · CIK 0001030575 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 10,000

F1 · security: Represents shares sold by Atlas Venture Fund IX, L.P. ("Atlas IX"). Atlas Venture Associates IX, L.P. ("AVA IX LP"), is the general partner of Atlas IX. Atlas Venture Associates IX, LLC ("AVA IX LLC") is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. The shares were sold by Atlas IX pursuant to a Rule 10b5-1 plan adopted by Atlas IX on March 1, 2021

F19 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices from $143.32 - $144.22, inclusive. The reporting person undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (19) of this Form 4.

F20 · ownership.nature: Represents shares held directly by Atlas IX. The general partner of Atlas IX is AVA IX LP. AVA IX LLC is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any.

SEC source: 0001104659-21-086607 · tm2120917-1_4seq1.xml · nonDerivative · entry 17

FORMELA JEAN FRANCOIS · CIK 0001030575 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 16,149

F1 · security: Represents shares sold by Atlas Venture Fund IX, L.P. ("Atlas IX"). Atlas Venture Associates IX, L.P. ("AVA IX LP"), is the general partner of Atlas IX. Atlas Venture Associates IX, LLC ("AVA IX LLC") is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. The shares were sold by Atlas IX pursuant to a Rule 10b5-1 plan adopted by Atlas IX on March 1, 2021

F18 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices from $142.32 - $143.31, inclusive. The reporting person undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (18) of this Form 4.

F20 · ownership.nature: Represents shares held directly by Atlas IX. The general partner of Atlas IX is AVA IX LP. AVA IX LLC is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any.

SEC source: 0001104659-21-086607 · tm2120917-1_4seq1.xml · nonDerivative · entry 16

FORMELA JEAN FRANCOIS · CIK 0001030575 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 29,705

F1 · security: Represents shares sold by Atlas Venture Fund IX, L.P. ("Atlas IX"). Atlas Venture Associates IX, L.P. ("AVA IX LP"), is the general partner of Atlas IX. Atlas Venture Associates IX, LLC ("AVA IX LLC") is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. The shares were sold by Atlas IX pursuant to a Rule 10b5-1 plan adopted by Atlas IX on March 1, 2021

F17 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices from $141.32 - $142.31, inclusive. The reporting person undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (17) of this Form 4.

F20 · ownership.nature: Represents shares held directly by Atlas IX. The general partner of Atlas IX is AVA IX LP. AVA IX LLC is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any.

SEC source: 0001104659-21-086607 · tm2120917-1_4seq1.xml · nonDerivative · entry 15

FORMELA JEAN FRANCOIS · CIK 0001030575 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 38,125

F1 · security: Represents shares sold by Atlas Venture Fund IX, L.P. ("Atlas IX"). Atlas Venture Associates IX, L.P. ("AVA IX LP"), is the general partner of Atlas IX. Atlas Venture Associates IX, LLC ("AVA IX LLC") is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. The shares were sold by Atlas IX pursuant to a Rule 10b5-1 plan adopted by Atlas IX on March 1, 2021

F16 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices from $140.32 - $141.31, inclusive. The reporting person undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (16) of this Form 4.

F20 · ownership.nature: Represents shares held directly by Atlas IX. The general partner of Atlas IX is AVA IX LP. AVA IX LLC is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any.

SEC source: 0001104659-21-086607 · tm2120917-1_4seq1.xml · nonDerivative · entry 14

FORMELA JEAN FRANCOIS · CIK 0001030575 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 46,152

F1 · security: Represents shares sold by Atlas Venture Fund IX, L.P. ("Atlas IX"). Atlas Venture Associates IX, L.P. ("AVA IX LP"), is the general partner of Atlas IX. Atlas Venture Associates IX, LLC ("AVA IX LLC") is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. The shares were sold by Atlas IX pursuant to a Rule 10b5-1 plan adopted by Atlas IX on March 1, 2021

F15 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices from $139.32 - $140.31, inclusive. The reporting person undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (15) of this Form 4.

F20 · ownership.nature: Represents shares held directly by Atlas IX. The general partner of Atlas IX is AVA IX LP. AVA IX LLC is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any.

SEC source: 0001104659-21-086607 · tm2120917-1_4seq1.xml · nonDerivative · entry 13

FORMELA JEAN FRANCOIS · CIK 0001030575 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 98,472

F1 · security: Represents shares sold by Atlas Venture Fund IX, L.P. ("Atlas IX"). Atlas Venture Associates IX, L.P. ("AVA IX LP"), is the general partner of Atlas IX. Atlas Venture Associates IX, LLC ("AVA IX LLC") is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. The shares were sold by Atlas IX pursuant to a Rule 10b5-1 plan adopted by Atlas IX on March 1, 2021

F14 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices from $138.32 - $139.31, inclusive. The reporting person undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (14) of this Form 4.

F20 · ownership.nature: Represents shares held directly by Atlas IX. The general partner of Atlas IX is AVA IX LP. AVA IX LLC is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any.

SEC source: 0001104659-21-086607 · tm2120917-1_4seq1.xml · nonDerivative · entry 12

FORMELA JEAN FRANCOIS · CIK 0001030575 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 102,673

F1 · security: Represents shares sold by Atlas Venture Fund IX, L.P. ("Atlas IX"). Atlas Venture Associates IX, L.P. ("AVA IX LP"), is the general partner of Atlas IX. Atlas Venture Associates IX, LLC ("AVA IX LLC") is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. The shares were sold by Atlas IX pursuant to a Rule 10b5-1 plan adopted by Atlas IX on March 1, 2021

F13 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices from $137.32 - $138.31, inclusive. The reporting person undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (13) of this Form 4.

F20 · ownership.nature: Represents shares held directly by Atlas IX. The general partner of Atlas IX is AVA IX LP. AVA IX LLC is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any.

SEC source: 0001104659-21-086607 · tm2120917-1_4seq1.xml · nonDerivative · entry 11

FORMELA JEAN FRANCOIS · CIK 0001030575 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 108,073

F1 · security: Represents shares sold by Atlas Venture Fund IX, L.P. ("Atlas IX"). Atlas Venture Associates IX, L.P. ("AVA IX LP"), is the general partner of Atlas IX. Atlas Venture Associates IX, LLC ("AVA IX LLC") is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. The shares were sold by Atlas IX pursuant to a Rule 10b5-1 plan adopted by Atlas IX on March 1, 2021

F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices from $136.32 - $137.31, inclusive. The reporting person undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (12) of this Form 4.

F20 · ownership.nature: Represents shares held directly by Atlas IX. The general partner of Atlas IX is AVA IX LP. AVA IX LLC is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any.

SEC source: 0001104659-21-086607 · tm2120917-1_4seq1.xml · nonDerivative · entry 10

FORMELA JEAN FRANCOIS · CIK 0001030575 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 111,106

F1 · security: Represents shares sold by Atlas Venture Fund IX, L.P. ("Atlas IX"). Atlas Venture Associates IX, L.P. ("AVA IX LP"), is the general partner of Atlas IX. Atlas Venture Associates IX, LLC ("AVA IX LLC") is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. The shares were sold by Atlas IX pursuant to a Rule 10b5-1 plan adopted by Atlas IX on March 1, 2021

F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices from $135.32 - $136.31, inclusive. The reporting person undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (11) of this Form 4.

F20 · ownership.nature: Represents shares held directly by Atlas IX. The general partner of Atlas IX is AVA IX LP. AVA IX LLC is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any.

SEC source: 0001104659-21-086607 · tm2120917-1_4seq1.xml · nonDerivative · entry 9

FORMELA JEAN FRANCOIS · CIK 0001030575 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 132,999

F1 · security: Represents shares sold by Atlas Venture Fund IX, L.P. ("Atlas IX"). Atlas Venture Associates IX, L.P. ("AVA IX LP"), is the general partner of Atlas IX. Atlas Venture Associates IX, LLC ("AVA IX LLC") is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. The shares were sold by Atlas IX pursuant to a Rule 10b5-1 plan adopted by Atlas IX on March 1, 2021

F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices from $134.32 - $135.31, inclusive. The reporting person undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (10) of this Form 4.

F20 · ownership.nature: Represents shares held directly by Atlas IX. The general partner of Atlas IX is AVA IX LP. AVA IX LLC is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any.

SEC source: 0001104659-21-086607 · tm2120917-1_4seq1.xml · nonDerivative · entry 8

FORMELA JEAN FRANCOIS · CIK 0001030575 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 163,830

F1 · security: Represents shares sold by Atlas Venture Fund IX, L.P. ("Atlas IX"). Atlas Venture Associates IX, L.P. ("AVA IX LP"), is the general partner of Atlas IX. Atlas Venture Associates IX, LLC ("AVA IX LLC") is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. The shares were sold by Atlas IX pursuant to a Rule 10b5-1 plan adopted by Atlas IX on March 1, 2021

F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices from $133.32 - $134.31, inclusive. The reporting person undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (9) of this Form 4.

F20 · ownership.nature: Represents shares held directly by Atlas IX. The general partner of Atlas IX is AVA IX LP. AVA IX LLC is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any.

SEC source: 0001104659-21-086607 · tm2120917-1_4seq1.xml · nonDerivative · entry 7

FORMELA JEAN FRANCOIS · CIK 0001030575 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 200,349

F1 · security: Represents shares sold by Atlas Venture Fund IX, L.P. ("Atlas IX"). Atlas Venture Associates IX, L.P. ("AVA IX LP"), is the general partner of Atlas IX. Atlas Venture Associates IX, LLC ("AVA IX LLC") is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. The shares were sold by Atlas IX pursuant to a Rule 10b5-1 plan adopted by Atlas IX on March 1, 2021

F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices from $132.32 - $133.31, inclusive. The reporting person undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (8) of this Form 4.

F20 · ownership.nature: Represents shares held directly by Atlas IX. The general partner of Atlas IX is AVA IX LP. AVA IX LLC is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any.

SEC source: 0001104659-21-086607 · tm2120917-1_4seq1.xml · nonDerivative · entry 6

FORMELA JEAN FRANCOIS · CIK 0001030575 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 256,537

F1 · security: Represents shares sold by Atlas Venture Fund IX, L.P. ("Atlas IX"). Atlas Venture Associates IX, L.P. ("AVA IX LP"), is the general partner of Atlas IX. Atlas Venture Associates IX, LLC ("AVA IX LLC") is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. The shares were sold by Atlas IX pursuant to a Rule 10b5-1 plan adopted by Atlas IX on March 1, 2021

F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $131.32 - $132.31, inclusive. The reporting person undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (7) of this Form 4.

F20 · ownership.nature: Represents shares held directly by Atlas IX. The general partner of Atlas IX is AVA IX LP. AVA IX LLC is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any.

SEC source: 0001104659-21-086607 · tm2120917-1_4seq1.xml · nonDerivative · entry 5

FORMELA JEAN FRANCOIS · CIK 0001030575 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 310,360

F1 · security: Represents shares sold by Atlas Venture Fund IX, L.P. ("Atlas IX"). Atlas Venture Associates IX, L.P. ("AVA IX LP"), is the general partner of Atlas IX. Atlas Venture Associates IX, LLC ("AVA IX LLC") is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. The shares were sold by Atlas IX pursuant to a Rule 10b5-1 plan adopted by Atlas IX on March 1, 2021

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $130.32 - $131.31, inclusive. The reporting person undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (6) of this Form 4.

F20 · ownership.nature: Represents shares held directly by Atlas IX. The general partner of Atlas IX is AVA IX LP. AVA IX LLC is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any.

SEC source: 0001104659-21-086607 · tm2120917-1_4seq1.xml · nonDerivative · entry 4

FORMELA JEAN FRANCOIS · CIK 0001030575 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 376,828

F1 · security: Represents shares sold by Atlas Venture Fund IX, L.P. ("Atlas IX"). Atlas Venture Associates IX, L.P. ("AVA IX LP"), is the general partner of Atlas IX. Atlas Venture Associates IX, LLC ("AVA IX LLC") is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. The shares were sold by Atlas IX pursuant to a Rule 10b5-1 plan adopted by Atlas IX on March 1, 2021

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $129.32 - $130.31, inclusive. The reporting person undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (5) of this Form 4.

F20 · ownership.nature: Represents shares held directly by Atlas IX. The general partner of Atlas IX is AVA IX LP. AVA IX LLC is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any.

SEC source: 0001104659-21-086607 · tm2120917-1_4seq1.xml · nonDerivative · entry 3

FORMELA JEAN FRANCOIS · CIK 0001030575 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 425,552

F1 · security: Represents shares sold by Atlas Venture Fund IX, L.P. ("Atlas IX"). Atlas Venture Associates IX, L.P. ("AVA IX LP"), is the general partner of Atlas IX. Atlas Venture Associates IX, LLC ("AVA IX LLC") is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. The shares were sold by Atlas IX pursuant to a Rule 10b5-1 plan adopted by Atlas IX on March 1, 2021

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $128.32 - $129.31, inclusive. The reporting person undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) of this Form 4.

F20 · ownership.nature: Represents shares held directly by Atlas IX. The general partner of Atlas IX is AVA IX LP. AVA IX LLC is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any.

SEC source: 0001104659-21-086607 · tm2120917-1_4seq1.xml · nonDerivative · entry 2

FORMELA JEAN FRANCOIS · CIK 0001030575 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 481,832

F1 · security: Represents shares sold by Atlas Venture Fund IX, L.P. ("Atlas IX"). Atlas Venture Associates IX, L.P. ("AVA IX LP"), is the general partner of Atlas IX. Atlas Venture Associates IX, LLC ("AVA IX LLC") is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. The shares were sold by Atlas IX pursuant to a Rule 10b5-1 plan adopted by Atlas IX on March 1, 2021

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $127.32 - $128.31, inclusive. The reporting person undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) of this Form 4.

F20 · ownership.nature: Represents shares held directly by Atlas IX. The general partner of Atlas IX is AVA IX LP. AVA IX LLC is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any.

SEC source: 0001104659-21-086607 · tm2120917-1_4seq1.xml · nonDerivative · entry 1

FORMELA JEAN FRANCOIS · CIK 0001030575 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 537,357

F1 · security: Represents shares sold by Atlas Venture Fund IX, L.P. ("Atlas IX"). Atlas Venture Associates IX, L.P. ("AVA IX LP"), is the general partner of Atlas IX. Atlas Venture Associates IX, LLC ("AVA IX LLC") is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. The shares were sold by Atlas IX pursuant to a Rule 10b5-1 plan adopted by Atlas IX on March 1, 2021

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $126.32 - $127.31, inclusive. The reporting person undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) of this Form 4.

F20 · ownership.nature: Represents shares held directly by Atlas IX. The general partner of Atlas IX is AVA IX LP. AVA IX LLC is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any.

SEC source: 0001209191-21-043374 · doc4.xml · derivative · entry 2

FORMELA JEAN FRANCOIS · CIK 0001030575 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,382

Underlying: Common Stock · 3,382 shares

Expires 2031-06-22

F2 · derivative.exercise_date: This option was granted on June 23, 2021 with respect to 3,382 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant.

SEC source: 0001209191-21-043374 · doc4.xml · nonDerivative · entry 1

FORMELA JEAN FRANCOIS · CIK 0001030575 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,094

F1 · security: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.